Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Purchases of Investments
Cash used to buy marketable securities and other investments.
Purchases of Investments history
Currency unavailable · from the cash flow
No Purchases of Investments data reported for this period type.
Purchases of Investments vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $408.23M USD | +226.5% | — | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $342.01M USD | -10.0% | — | 1710.1% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $225.93M USD | -1.5% | +35.9% | — |
| LTM Mar 2026 | $69.05M USD | -79.2% | -31.5% | 31.7% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $44.84M USD | — | — | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $39.52M USD | -76.9% | -27.6% | — |
| LTM Mar 2026 | $0 USD | — | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | -10.0% | -27.6% | 870.9% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.